FGFR4 and hepatocellular carcinoma: In view of the increased stemness gene expression observed with repression of FGFR4 signaling, clinical development of FGFR4 inhibitors will benefit from complementary therapeutics that target the resistant liver stem cell-like population concurrently to achieve superior outcome in HCC patients.